Scinai Immunotherapeutics Ltd.
A Jerusalem-based biopharmaceutical company that develops tiny antibody fragments called NanoAbs, derived from alpacas, to treat inflammatory and skin conditions, and also runs a contract manufacturing service for other biotech startups. It began life in 2003 as BiondVax Pharmaceuticals, focused on a universal flu vaccine, before rebranding as Scinai in 2023. The name is a stylized take on Sinai, the biblical mountain, chosen to mark a fresh start.
American Depositary Shares (ADS), each representing ordinary shares
Granted 400.00M
Granted 120.00M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Reichman AmirChief Executive Officer, Director · 1 transaction | — | 711.64M | 400.00M | — | — |
| Germain MarkDirector · 1 transaction | — | 120.00M | 120.00M | — | — |
Select a row to see that insider’s individual transactions.